All In Biotech

Free tool

FAERS Monitor: Dawnzera (Autoinjector)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219407 or its brand name (Dawnzera (Autoinjector), Donidalorsen Sodium). Reports on generic versions are filed under their own applications.

Reports

506

Serious

55

11% of reports

Hospitalization

32

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hereditary angioedema215
  • injection site pain41
  • headache31
  • injection site erythema27
  • injection site bruising20
  • nausea19
  • abdominal distension18
  • fatigue18
  • dizziness17
  • peripheral swelling17
  • abdominal pain15
  • malaise13
  • swelling13
  • diarrhoea12
  • upper respiratory tract infection12

Reports by year received

View as table
YearReports
20255
2026501

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,653 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hereditary angioedemaSignal215849.8766.5177,886
upper respiratory tract infectionSignal1210.86.297
injection site bruisingSignal2010.46.8162
injection site erythemaSignal279.06.3186
abdominal distensionSignal187.24.690
swellingSignal135.83.447
injection site painSignal415.64.1151
peripheral swellingSignal174.62.944
abdominal painSignal152.71.614
headacheSignal312.11.516
dizziness171.40.92
malaise131.20.70
nausea191.00.60
fatigue181.00.60
diarrhoea120.80.41

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.